|Videos|May 17, 2017
Choosing Frontline and Second-line Therapy for NSCLC
Advertisement
Mark A. Socinski, MD, Florida Hospital Cancer Institute, discusses how to decide first-line therapy, second-line therapy, and beyond for patients with non—small cell lung cancer.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts NDA for Zanzalintinib Plus Atezolizumab in Pretreated mCRC
2
Retrospective, Real-World Analysis Shows Improved OS With Apalutamide Over Darolutamide in mCSPC
3
SC Daratumumab Plus VRd Expands Options in Newly Diagnosed, Transplant-Ineligible Myeloma
4
HPV Vaccination and Evolving Screening Strategies Continue to Shape Cervical Cancer Prevention Efforts
5































